There were cheers from Steadymed (NASDAQ:STDY) investors last Friday following The Patent Trial and Appeal Board’s (PTAB) favorable decision granted to the biotech firm …
As REDUCE-IT continues to track to expected read-outs in early 2018, H.C.
Nivalis Therapeutics Inc (NASDAQ:NVLS) investors are heading for the hills after the drug maker reported that the Phase 2 study of cavosonstat as an …
TG Therapeutics Inc (NASDAQ:TGTX) shares crashed almost 17% yesterday on back of the biotech firm’s announcement that it has filed with the FDA …
In a research report released today, H.C.
H.C.
At last week’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference, Biogen Inc (NASDAQ:BIIB) provided “further clarity” on the “unexpected …
Last week, Biogen Inc (NASDAQ:BIIB) published its Phase 1b PRIME clinical trial coupled with supporting preclinical data in the latest volume of Nature. In …
In ACADIA Pharmaceuticals Inc.’s (NASDAQ:ACAD) second-quarter report, investors got a first glimpse of Nuplazid’s early launch in Parkinson’s disease psychosis (PDP).
In a research report issued Friday, H.C.